Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab alone or with vinblastine in older patients with classical Hodgkin lymphoma and comorbidities
2017-001939-38Phase 2Completed
- Sponsor
- LYSARC
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and vinblastine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by LYSARC. Primary endpoint: Complete Metabolic Response rate at end of treatment. Started Feb 2018; status: completed.
02
Drugs
nivolumabvinblastine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2017-001939-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001939-38.